Alvotech

Alvotech is a vertically integrated biotechnology company dedicated exclusively to the development and manufacture of biosimilar medicines. The company identifies, researches, and produces biosimilars across therapeutic areas such as autoimmune disorders, oncology, eye conditions, respiratory illness, and bone diseases. Rather than selling directly to end consumers or healthcare providers, Alvotech out-licenses its commercial rights to leading global and regional pharmaceutical partners, who handle local distribution and sales in exchange for milestones and royalties.

The company operates a primary 280,000-square-foot manufacturing and research complex in Reykjavik, Iceland, alongside additional facilities, operations, and support centers across Sweden, Switzerland, Germany, India, and the United States. Employing approximately 1,500 people globally, Alvotech commercializes products in more than 30 markets with intentions to expand across over 90 markets worldwide. Corporate headquarters are situated in Reykjavik, Iceland, with a principal place of business in Luxembourg.

Summary of the business section of Alvotech's latest annual report, written by StockData.

“The CSDDD, which entered into force in July 2024, imposes extensive value‑chain due‑diligence obligations and a climate transition‑plan requirement on companies meeting updated thresholds (including ≥1,000 employees and ≥€450 million net worldwide turnover), with application now deferred to July 2028 for the largest companies under the Stop‑the‑Clock Directive; however, the scope may be further reduced as negotiations on additional amendments continue.”